CARDIOR
Key Facts
| Invested since | 2017 |
| Based in | Lower Saxony |
About the company
Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a strategic pharma partner after clinical proof-of-concept (POC) data.
Do you want to
know more about this company?
CARDIOR in the news
Zum Artikel
Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease
Zum Artikel
Cardior Pharmaceuticals raises €15 million to develop first-in-class ncRNA therapeutics and diagnostics for patients with myocardial infarction and heart failure
More startups from Life Sciences
MDA was founded in 2023 by Dr Gunter Trojandt, Annett Christ and two business angels, Jozsef Bugovics and Nils Kröber. MDA has a total of 10 employees and is based …
To the complete profileof Medical Decision Alliance
Exit
Rigontec GmbH is a preclinical biotech company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases. Rigontec’s lead compound ImOl100 targets a novel receptor of the innate immune …
To the complete profileof Rigontec
Exit
GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with …
To the complete profileof GQ Bio Therapeutics
Ebenbuild is a health tech pioneer that creates personalized treatment recommendations for mechanical ventilation and ICU patient care for clinical users. Founded in Munich in 2019, the company develops software …
To the complete profileof Ebenbuild
Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility …
To the complete profileof Tacalyx
Signatope develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays. SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in …
To the complete profileof Signatope
IOP GmbH will initiate a paradigm chance in glaucoma therapy by its products for telemetric, 24 hour monitoring of intraocular pressure, allowing personalized patient management.
To the complete profileof Implandata Ophthalmic Products
Exit
The founders of Kumovis GmbH have set themselves the goal of enabling the additive production of plastic implants and are developing innovative 3D printers specifically for medical products. Kumovis focuses …
To the complete profileof Kumovis
Exit
KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare. Exit since Feb. 2011. Purchaser: Evotec AG
To the complete profileof KINAXO
Exit
Lipocalyx develops transfection reagents. Our Viromers® are polymers emulating a viral mechanism for cell entry. The company provides reagents and currently establishes services for pharmaceutical applications.
To the complete profileof Lipocalyx
Exit
LOEWI GmbH is a scientific spin-off of the TU München with the mission to make personalized health and nutrition available to everyone by combining science and technology. LOEWI’s patented personalization …
To the complete profileof LOEWI
Exit
RIMASYS offers prefractures specimen for educational purposes in the field of orthopedic surgery. The innovative MedTech company is setting new standards in surgical education and implant development through innovative education …
To the complete profileof RIMASYS